First-pass extracted concept

CRISPR-Cas technologies

Candidate: concept label2 source documents4 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

CRISPR-Cas technologies are described as tools for precise DNA and RNA modulation in neurodegenerative disease contexts. The abstract states they can correct pathogenic mutations, suppress toxic gene expression, and restore neuronal function.

Source 1DOI PubMed

What problem it solves

The review frames these technologies as potential disease-modifying interventions for disorders including AD, PD, HD, and ALS.

Source 1DOI PubMed

What it does not solve

The abstract explicitly notes unresolved challenges in blood-brain barrier delivery, immune responses, long-term safety, and ethical and regulatory issues.

Source 1DOI PubMed

Alternatives

Advanced CRISPR modalities and diagnostics are discussed within the CRISPR-Cas umbrella, but no non-CRISPR therapeutic alternative is explicitly contrasted in the abstract.

Source 1DOI PubMed

Evidence Snippets

CRISPR-Cas genome-editing technologies have emerged as powerful tools for precise DNA and RNA modulation

Evidence 1Source 1DOI PubMedprovenance

These innovations, alongside the development of CRISPR-Cas technologies, have significantly enhanced the precision, efficiency, and scalability of genetic screening approaches.

Evidence 2Source 2DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Source 2primary paper2025MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Linked Claims

Claim 1mechanistic capabilitysupports2025Source 1DOI PubMed

Preclinical and early translational studies demonstrate that CRISPR-Cas platforms can correct pathogenic mutations, suppress toxic gene expression, and restore neuronal function.

Claim 2performance improvementsupports2025Source 2DOI PubMed

Recent innovations together with CRISPR-Cas technologies have enhanced the precision, efficiency, and scalability of genetic screening approaches.

Quoted textsource-backed

These innovations, alongside the development of CRISPR-Cas technologies, have significantly enhanced the precision, efficiency, and scalability of genetic screening approaches.

Claim 3therapeutic potentialsupports2025Source 1DOI PubMed

CRISPR-Cas genome-editing technologies offer promising therapeutic strategies for neurodegenerative disorders including AD, PD, HD, and ALS.

Claim 4translational limitationsupports2025Source 1DOI PubMed

Major translational challenges for CRISPR-Cas neurodegenerative applications include efficient delivery across the blood-brain barrier, immune responses, long-term safety, and ethical and regulatory considerations.